Profile data is unavailable for this security.
About the company
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
- Revenue in SEK (TTM)3.50bn
- Net income in SEK-3.84bn
- Incorporated1989
- Employees1.13k
- LocationVitrolife ABGustaf Werners gata 2, Vastra FrolundaGOETEBORG 421 32SwedenSWE
- Phone+46 317218000
- Fax+46 317218099
- Websitehttps://www.vitrolife.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 1.21bn | -466.18m | 7.01bn | 195.00 | -- | 18.85 | -- | 5.81 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 9.30 | 6,189,175.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Surgical Science Sweden AB | 842.02m | 207.95m | 7.23bn | 265.00 | 34.76 | 1.58 | 27.30 | 8.59 | 4.08 | 4.08 | 16.51 | 89.92 | 0.1749 | 1.68 | 6.12 | 3,238,531.00 | 4.32 | 4.49 | 4.59 | 4.78 | 68.59 | 70.06 | 24.70 | 23.75 | 3.53 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Gubra A/S | 318.92m | -69.26m | 7.68bn | 219.00 | -- | 10.26 | -- | 24.09 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Swedencare AB (publ) | 2.41bn | 71.50m | 8.94bn | 552.00 | 125.10 | 1.15 | 23.33 | 3.71 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.30bn | 371.25m | 12.92bn | 211.00 | 36.12 | 6.19 | 32.64 | 9.93 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| AddLife AB | 9.80bn | 79.00m | 13.42bn | 2.29k | 175.69 | 2.69 | 13.18 | 1.37 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Bonesupport Holding AB | 655.75m | 266.56m | 16.06bn | 121.00 | 60.42 | 28.38 | 57.97 | 24.49 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| BioArctic AB | 252.21m | -122.17m | 17.27bn | 90.00 | -- | 20.85 | -- | 68.46 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Bavarian Nordic A/S | 10.33bn | 1.53bn | 21.72bn | 1.38k | 13.90 | 1.37 | 8.85 | 2.10 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 3.50bn | -3.84bn | 25.41bn | 1.13k | -- | 1.92 | -- | 7.26 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 1.82bn | 450.48m | 33.13bn | 218.00 | 73.81 | 12.52 | 71.27 | 18.18 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 7.69bn | 863.39m | 47.90bn | 2.83k | 60.99 | 7.17 | 36.14 | 6.23 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Data as of May 21 2024. Currency figures normalised to Vitrolife AB's reporting currency: Swedish Krona SEK
23.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AMF Fonder ABas of 04 Jan 2024 | 6.90m | 5.09% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 5.48m | 4.04% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 4.76m | 3.52% |
| Handelsbanken Fonder ABas of 30 Apr 2024 | 2.88m | 2.13% |
| SEB Investment Management ABas of 30 Apr 2024 | 2.73m | 2.02% |
| The Vanguard Group, Inc.as of 09 May 2024 | 2.33m | 1.72% |
| Cliens Kapitalf�rvaltning ABas of 31 Aug 2023 | 2.28m | 1.68% |
| Tredje AP-fondenas of 31 Aug 2023 | 1.74m | 1.29% |
| Norges Bank Investment Managementas of 31 Aug 2023 | 1.53m | 1.13% |
| C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2023 | 1.33m | 0.99% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
